Source: ScreenPro.
  • ScreenPro (SCRN) has welcomed back Andrew Ryu as its interim Chairman and CEO
  • Former CEO and Director, Lena Kozovski, will remain with the company until the end of the year for operational support
  • Ryu brings over 20 years of operational experience with a focus on public and private M&A
  • ScreenPro is a medical technology company offering turnkey screening solutions through its proprietary medical alerting software
  • ScreenPro (SCRN) is unchanged trading at $0.025 per share

ScreenPro (SCRN) has welcomed back Andrew Ryu as its interim Chairman and CEO.

Former CEO and Director, Lena Kozovski, has stepped down from her duties, but will remain with the company until the end of the year as an operational aid.

Former Chairman, Michael Yeung, has also stepped down from the board.

Ryu greatly contributed to ScreenPro’s past success in his previous term as interim Chairman and CEO.

He holds over 20 years of operational experience with a focus on public and private M&A and was nominated as EY Entrepreneur of the Year in 2014.

He previously served as Executive Chairman of Graph Blockchain (GBLC) and Datametrex AI (DM).

“It is with great pleasure that I take on the position as CEO and take the leadership role in operations to help contribute to the company’s success and its value,” stated Ryu. “I believe my wealth of operational and entrepreneurial experience will take the company to new heights and elevate ScreenPro to reach its highest potential.”

ScreenPro is a medical technology company offering turnkey screening solutions through its proprietary medical alerting software.

ScreenPro (SCRN) is unchanged trading at $0.025 per share as of 12:06 pm EST.


More From The Market Online

KWESST to provide situational awareness for the Canadian Red Cross

KWESST Micro Systems (TSXV:KWE) wins a contract to provide a situational awareness app to support the Canadian Red Cross.

Reliq Health expands contract with U.S. health group

Reliq Health Technologies (TSXV:RHT) reveals it has expanded an existing contract with a large U.S. health group.